New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at this year's European Renal Association (ERA) Congress in Glasgow, June 3-6. The presentations reinforce our ambition to advance scientific understanding across progressive immune-mediated kidney diseases and support the evolution of kidney care.

GlobeNewsWire • May 26, 2026

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress.

GlobeNewsWire • May 21, 2026

US Supreme Court rebuffs pharma challenge to Biden-era drug price

The U.S. Supreme Court declined on Monday to hear a pharmaceutical industry challenge to a plan ​to curb Medicare drug prices adopted during Democratic former President Joe Biden's administration that drugmakers argued ‌illegally forces them to accept steep discounts and jeopardizes innovation.

Reuters • May 18, 2026

Cancer Stocks That Are Advancing the Future of Oncology Care

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

Zacks Investment Research • May 18, 2026

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026.

GlobeNewsWire • May 17, 2026

Health Rounds: Common ADHD medicines help treat cancer-related fatigue

We also report on findings that help explain why ​the flu can be particularly dangerous for pregnant women and that open the door to potential future treatments.

Reuters • May 15, 2026

Implied Volatility Surging for Novartis Stock Options

Investors need to pay close attention to NVS stock based on the movements in the options market lately.

Zacks Investment Research • May 13, 2026

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23 billion investment in US manufacturing and research. The start of construction on the company's first Texas‑based manufacturing facility brings US RLT production closer to patients across the southern US, becoming the fifth RLT site nationwide. “Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale,” said Vas Narasimhan, CEO of Novartis. “Breaking ground in Denton further strengthens our US supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them.” This expansion reinforces Novartis' leadership as the first company to deliver RLT at scale, building the network capacity needed as these therapies extend into earlier stages of treatment and a broader range of cancers. Announced earlier this year, the site is expected to become operational in 2028 and create new US-based Novartis jobs in bioengineering, advanced manufacturing, quality, and operations, supporting economic growth in Denton and surrounding communities.  US Under Secretary of Commerce for Industry and Security Jeffrey Kessler, Swiss Ambassador to the US Ralf Heckner, Texas State Senator Brent Hagenbuch, Texas State Representative Andy Hopper, and Denton Mayor Gerard Hudspeth joined Novartis leadership, employees, and community partners to celebrate the start of construction.  “I'm pleased to welcome Novartis to Denton as their newest manufacturing location for their cancer therapies,” said Texas State Senator Brent Hagenbuch. “Their decision establishes a strong partnership and reflects the unique opportunity Denton provides to a well-educated workforce, and the unique access the new plant location will provide to the vibrant North Texas economy and rapidly growing state population.” The Texas facility bolsters the Novartis coast-to-coast RLT manufacturing network, with existing US sites in New Jersey, Indiana and California, and a new site being added in Florida. The Denton site adds to the largest US RLT manufacturing network and further builds on the company's longstanding track record of enabling >99% of doses to be administered on the planned day of treatment. Each dose of RLT is custom-made and requires precise coordination, making manufacturing reliability and proximity to treatment centers critical to delivering treatment as planned. In April 2025, Novartis committed $23 billion over five years to grow its US research and manufacturing footprint. Seven new and three expanded facilities across the country are already under construction – part of the company's broader effort to manufacture all key medicines for US patients in the US, supporting supply resilience and dependable delivery of medicines. The Denton groundbreaking builds on rapid progress across Novartis' US investment plan.

GlobeNewsWire • May 7, 2026

Novartis to cut 220 jobs as it closes German site

Swiss drugmaker Novartis ​said on Tuesday ‌that it is set ​to ​cut around 220 jobs ⁠in ​Germany as part ​of the planned closure of ​a production ​site by the ‌end ⁠of 2028.

Reuters • May 5, 2026

UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies

Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giants have recently said that Europe risks losing out on new medicines as drug prices in the U.S. market are tied to lower prices elsewhere under Trump's MFN policy.

CNBC • Apr 29, 2026